Pyrrolo[2,3-D]pyrimidine compounds
USRE41783E1 · kind E1 · reissue
16Cited by
32References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 13, 2009 |
| Grant date | Sep 28, 2010 |
| Priority date | — |
| Expiry date | Oct 13, 2029 |
Classification
- Technology area (CPC —)General
Abstract
A compound of the formula wherein R1, R2 and R3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.